Curis , Development Candidate CUDC-101 and Its Targeted Cancer Drug Development Platform

Sept. 25, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, provided an update on CUDC-101 and other preclinical drug candidates under its Targeted Cancer Drug Development Platform... CUDC-101 displays anti-proliferation and apoptosis, or programmed cell death, inducing activities in vitro against a broad range of cancer cell types including lung, breast, prostate, colon, liver and pancreas... Curis' Press Release -